DrugPatentWatch Database Preview
Drugs in Development Information for Azacytidine
» See Plans and Pricing
What is the drug development status for Azacytidine?
Azacytidine is an investigational drug.
There have been 145 clinical trials for Azacytidine.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2019.
The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, and Leukemia. The leading clinical trial sponsors are National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Celgene Corporation.
There are two US patents protecting this investigational drug and thirty-two international patents.
Summary for Azacytidine
| US Patents | 2,209 |
| International Patents | 32,449 |
| US Patent Applications | 4,849 |
| WIPO Patent Applications | 2,424 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 3 (2019-04-01) |
| Vendors | 91 |
Recent Clinical Trials for Azacytidine
| Title | Sponsor | Phase |
|---|---|---|
| Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | M.D. Anderson Cancer Center | Phase 1/Phase 2 |
| Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for Azacytidine
Top disease conditions for Azacytidine
Top clinical trial sponsors for Azacytidine
US Patents for Azacytidine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Azacytidine | Start Trial | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE) | Start Trial |
| Azacytidine | Start Trial | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | Start Trial |
| Azacytidine | Start Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | Start Trial |
| Azacytidine | Start Trial | Constructs containing multiple expression cassettes for cancer therapy | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (Jerusalem, IL) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Azacytidine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Azacytidine | Argentina | 104113 | 2035-03-27 | Start Trial |
| Azacytidine | Argentina | 112781 | 2035-03-27 | Start Trial |
| Azacytidine | Australia | 2016239920 | 2035-03-27 | Start Trial |
| Azacytidine | Australia | 2018232952 | 2035-03-27 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
